Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
920 patients (estimated)
Sponsors
Hoffmann-La Roche
Tags
Pan-RAF Kinase Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1714
NCT Identifier
NCT04589845

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.